IRIS
SCARFO', LYDIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.670
AS - Asia 3.594
EU - Europa 3.409
SA - Sud America 902
Continente sconosciuto - Info sul continente non disponibili 295
AF - Africa 59
OC - Oceania 18
Totale 11.947
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.513
RU - Federazione Russa 1.940
SG - Singapore 1.235
CN - Cina 1.123
BR - Brasile 740
HK - Hong Kong 548
IT - Italia 382
SE - Svezia 338
VN - Vietnam 280
DE - Germania 169
FR - Francia 169
BD - Bangladesh 118
GB - Regno Unito 94
CA - Canada 73
AR - Argentina 72
FI - Finlandia 65
IN - India 59
MX - Messico 46
AT - Austria 38
EC - Ecuador 33
IQ - Iraq 33
PL - Polonia 32
NL - Olanda 30
ID - Indonesia 29
JP - Giappone 29
ES - Italia 26
IE - Irlanda 24
GR - Grecia 21
CO - Colombia 19
AU - Australia 18
TR - Turchia 18
ZA - Sudafrica 18
BE - Belgio 17
UA - Ucraina 16
VE - Venezuela 16
AE - Emirati Arabi Uniti 15
PK - Pakistan 15
PY - Paraguay 12
MY - Malesia 11
SA - Arabia Saudita 11
TN - Tunisia 10
IL - Israele 9
MD - Moldavia 8
NP - Nepal 8
JM - Giamaica 7
LT - Lituania 7
MA - Marocco 7
UZ - Uzbekistan 7
KE - Kenya 6
NO - Norvegia 6
ET - Etiopia 5
HN - Honduras 5
JO - Giordania 5
BB - Barbados 4
BH - Bahrain 4
KZ - Kazakistan 4
LU - Lussemburgo 4
PA - Panama 4
PH - Filippine 4
SN - Senegal 4
TH - Thailandia 4
AL - Albania 3
AZ - Azerbaigian 3
CH - Svizzera 3
CL - Cile 3
CR - Costa Rica 3
CZ - Repubblica Ceca 3
DK - Danimarca 3
EG - Egitto 3
GT - Guatemala 3
KR - Corea 3
LB - Libano 3
LV - Lettonia 3
PE - Perù 3
SV - El Salvador 3
UY - Uruguay 3
AM - Armenia 2
DO - Repubblica Dominicana 2
GD - Grenada 2
GE - Georgia 2
IR - Iran 2
KH - Cambogia 2
KW - Kuwait 2
RS - Serbia 2
TW - Taiwan 2
AI - Anguilla 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BY - Bielorussia 1
BZ - Belize 1
DZ - Algeria 1
GP - Guadalupe 1
HU - Ungheria 1
LS - Lesotho 1
LY - Libia 1
ML - Mali 1
NA - Namibia 1
NI - Nicaragua 1
Totale 11.645
Salva come PNG Salva come JPEG
Città #
Dallas 1.398
Singapore 641
Hong Kong 543
Moscow 447
Ashburn 389
San Jose 298
Shanghai 225
Beijing 156
Hefei 149
New York 140
Lauterbourg 127
Ho Chi Minh City 97
Lawrence 97
Princeton 97
Milan 90
Los Angeles 68
Hanoi 57
Nuremberg 56
São Paulo 54
Santa Clara 49
Rome 48
Munich 44
Boardman 41
Warsaw 29
Council Bluffs 26
Buffalo 25
Helsinki 24
Chennai 23
Dublin 23
Tokyo 23
Denver 22
Montreal 22
Houston 21
Orem 21
Rio de Janeiro 20
Turku 20
Boston 19
Da Nang 19
Guangzhou 19
Vienna 19
Brooklyn 18
Hangzhou 18
Chicago 17
Phoenix 17
Poplar 17
Thessaloniki 17
Atlanta 14
Brasília 14
Frankfurt am Main 14
Lappeenranta 14
London 13
Manchester 13
Mexico City 13
Johannesburg 12
Naples 12
Porto Alegre 12
Stockholm 12
Baghdad 11
Belo Horizonte 11
Toronto 11
Brussels 10
Columbus 10
Curitiba 10
Las Vegas 10
Monza 10
Querétaro 10
Shenzhen 10
Amsterdam 9
Guarulhos 9
Quito 9
Ribeirão Preto 9
Asunción 8
Biên Hòa 8
Dubai 8
Guayaquil 8
Haiphong 8
Oviedo 8
San Francisco 8
Seattle 8
The Dalles 8
Wuxi 8
Bari 7
Florianópolis 7
Genoa 7
Jakarta 7
Mumbai 7
Ninh Bình 7
Turin 7
Zhengzhou 7
Buenos Aires 6
Cleveland 6
Dhaka 6
Goiânia 6
Istanbul 6
Jiaxing 6
Kuala Lumpur 6
Manaus 6
Medellín 6
Mol 6
Nairobi 6
Totale 6.274
Salva come PNG Salva come JPEG
Nome #
Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in mice: Lymphoma 452
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort 429
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker: CHRONIC LYMPHOCYTIC LEUKEMIA 428
Exploring Perceptions, Opinions, and Needs of Adult and Pediatric Cancer Patients, Caregivers, and Healthcare Professionals Towards Low-Fidelity Versions of the MyPal Project's Applications: Findings from 12 Pre-Pilot Focus Groups in 4 European Countries of an ePRO Intervention for Palliative Cancer Care (Preprint) 199
A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression 151
3D co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents 150
Chronic lymphocytic leukaemia 135
A novel Rag2(-/-)gamma(-/-)(c)-xenograft model of human CLL 127
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency 124
3D Bioprinting Allows the Establishment of Long-Term 3D Culture Model for Chronic Lymphocytic Leukemia Cells 119
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS-CoV-2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL 116
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study 113
A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia 112
Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models 110
Disrupting pro-survival and inflammatory pathways with dimethyl fumarate sensitizes chronic lymphocytic leukemia to cell death 109
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 104
Detection of clinically relevant variants in the TP53 gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL 103
Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia 103
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL 100
IκBε deficiency accelerates disease development in chronic lymphocytic leukemia 99
EZN-2208 treatment suppresses chronic lymphocytic leukaemia by interfering with environmental protection and increases response to fludarabine 99
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib 98
CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL 96
In Vitro Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors 96
Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes 96
HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment 95
A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemia 94
General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. 94
Bone Marrow Histopathology in the Diagnostic Evaluation of Splenic Marginal-zone and Splenic Diffuse Red Pulp Small B-cell Lymphoma: A Reliable Substitute for Spleen Histopathology? 93
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial 91
A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib 91
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia 91
Targeting B-cell anergy in chronic lymphocytic leukemia. 90
Assessing Patients' Knowledge on Chronic Lymphocytic Leukemia: Validation of the ERIC CLL Knowledge Questionnaire in Greece 90
T cell receptor gene repertoire profiles in subgroups of patients with chronic lymphocytic leukemia bearing distinct genomic aberrations 89
PYK2 is overexpressed in chronic lymphocytic leukaemia: A potential new therapeutic target 88
Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study) 88
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study 88
Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis 88
Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia 88
Interleukin-1 receptor-associated kinase 4 inhibitor interrupts toll-like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis 85
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 84
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience 83
Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia 82
Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients 82
3D-STED Super-Resolution Microscopy Reveals Distinct Nanoscale Organization of the Hematopoietic Cell-Specific Lyn Substrate-1 (HS1) in Normal and Leukemic B Cells 82
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling 80
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 78
COVID-19 and Chronic Lymphocytic Leukemia: Where We Stand Now 78
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL 78
Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line 78
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial 77
MINIMAL RESIDUAL DISEASE-DRIVEN TREATMENT INTENSIFICATION WITH SEQUENTIAL ADDITION OF IBRUTINIB TO VENETOCLAX IN R/R CLL 77
Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study 76
Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia 76
The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia. 74
Real-world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience 74
Loss of CYLD promotes splenic marginal zone lymphoma 73
Monoclonal B lymphocytosis in the general population 73
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients 72
CLL-like monoclonal B-cell lymphocytosis: are we all bound to have it? 72
Dimethyl itaconate selectively targets inflammatory and metabolic pathways in chronic lymphocytic leukemia 71
Reprogramming cell death: BCL2 family inhibition in hematological malignancies 71
Trabectedin reveals a strategy of immunomodulation in chronic lymphocytic leukemia 71
MyPal-Child study protocol: An observational prospective clinical feasibility study of the MyPal ePRO-based early palliative care digital system in paediatric oncology patients 71
MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27 70
Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL 70
Clinical features, management and prognosis of multifocal primary bone lymphoma: A retrospective study of the international extranodal lymphoma study group (the IELSG 14 study) 69
Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma 69
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY 68
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature 68
Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2 68
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY 67
Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia 67
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group 67
Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia 67
Profiling the Genomic Landscape at the Early Stages of CLL: Low Genomic Complexity and Paucity of Driver Mutations in MBL and Indolent CLL 67
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 – VERITAS study 66
Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment 66
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia 66
Monoclonal B Cell Lymphocytosis in Hepatitis C Virus Infected Individuals 65
Relevance of Minimal Residual Disease in the Era of Targeted Agents 64
Co-Designing Smartphone Notifications According to the Clinical Routine of Cancer Patients 63
MyPal ADULT study protocol: A randomised clinical trial of the MyPal ePRO-based early palliative care system in adult patients with haematological malignancies 63
Infrequent "chronic lymphocytic leukemia-specific" immunoglobulin stereotypes in aged individuals with or without low count monoclonal B cell lymphocytosis 62
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study 61
T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities 61
Fostering Palliative Care Through Digital Intervention: A Platform for Adult Patients With Hematologic Malignancies 60
Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors 60
No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy 59
Highly similar genomic landscapes in monoclonal b-cell lymphocytosis and ultra-stable chronic lymphocytic leukemia with low frequency of driver mutations 59
Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy 59
The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia 58
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report 58
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 58
Exploiting B Cell Receptor Stereotypy to design Tailored Immunotherapy in Chronic Lymphocytic Leukemia 58
Computational analysis of the evolutionarily conserved Missing In Metastasis/Metastasis Suppressor 1 gene predicts novel interactions, regulatory regions and transcriptional control 58
Targeting macrophages sensitizes chronic lymphocytic leukemia to apoptosis and inhibits disease progression 57
BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia 57
Single cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib 57
Totale 9.356
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.186
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.186
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202275 0 0 0 21 6 3 8 19 7 6 2 3
2022/2023616 215 113 54 1 16 82 23 34 40 8 11 19
2023/2024477 13 20 27 119 22 71 4 27 1 12 44 117
2024/20252.285 276 53 63 60 87 164 243 215 393 340 182 209
2025/20268.036 544 1.018 1.057 992 542 191 555 487 1.798 375 221 256
2026/2027364 254 110 0 0 0 0 0 0 0 0 0 0
Totale 11.947